Research
Hormonal
SGLT2 inhibitors and GLP-1 receptor agonists offer weight loss and glycaemic control, with SGLT2 inhibitors providing cardiovascular protection beyond glucose lowering and GLP-1 agonists showing early evidence of CVD event reduction.
Newer diabetes medications like SGLT2 inhibitors and GLP-1 agonists not only lower blood sugar but also help with weight loss and may protect the heart. They are often preferred for patients who are overweight or have high cardiovascular risk, offering benefits beyond just glucose control.
ModerateSupportsMEDIUM confidence
Pooled data from regulatory submissions and published trials suggest that SGLT2 inhibitors offer a magnitude of cardiovascular protection greater than might be expected by reductions in HbA1c alone [90, 91]. ... early data to support reductions in cardiovascular events with these agents also [96].
Why this rating
Based on pooled data and early trial evidence, not long-term RCTs for all agents mentioned.
Source
Management of type 2 diabetes: <scp>t</scp> he current situation and key opportunities to improve care in the <scp>UK</scp>
Steve Baín et al. · Diabetes Obesity and Metabolism · 2016
DOI 10.1111/dom.12760
narrative_reviewCited 24×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Intensive glucose control using sulphonylurea-insulin therapy in type 2 diabetes reduces long-term cardiovascular events and mortality, with a legacy effect persisting after the active intervention ends.Good
- Intensive lifestyle intervention in type 2 diabetes leads to significant weight loss and improved glycaemic control, but does not reduce cardiovascular morbidity or mortality over 10 years.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →